TUBERCULOSIS (TB) IS THE second leading cause of death from infectious disease in the world and remains a major public health problem throughout the Pacific basin. 1a Further exacerbating the global TB problem is the continuing emergence of multidrug-resistant (MDR) TB. Higher morbidity and mortality rates occur with MDR-TB than with drugsusceptible TB. MDR-TB is resistant to treatment with isoniazid and rifampin-the two most potent first-line TB drugs.
1b Diagnosis and treatment of MDR-TB in endemic areas is a relatively new public health challenge. Successful response requires isolation of infectious patients, rapid procurement of and treatment with second-line medications, and consistent directly observed therapy (DOT). On a global scale, many rural communities do not have adequate resources or the expertise needed to address this daunting public health problem.
The Federated States of Micronesia is a US-affiliated jurisdiction that comprises more than 600 islands dotted across 1 million square miles in the western Pacific Ocean. Micronesia is a low-income country where 27% of the people live below the US poverty line. 2 With funds from the Micronesia national government and US Department of the Interior, an adequate supply of second-line TB drugs was immediately purchased. These medications were selected in consultation with CDC experts. As a major program accomplishment, local access to national and international subject-matter experts was greatly enhanced.
Chuuk lacked the infrastructure and experience required to deliver daily intravenous medication outside of the hospital. In August 2008, a temporary MDR-TB isolation unit was constructed in an abandoned area of the hospital; local breezes and electric window fans were used to create a negative-flow environment. Initially six patients, five of whom were children, were identified for inpatient treatment. By January 2009, 10 additional cases were diagnosed and included in the MDR-TB cohort.
Current CDC and WHO standards for treatment for a typical case of MDR-TB recommend 6 to 9 months of intravenous therapy along with 18 to 24 months of oral second-line drugs. Understandably, families were reluctant to commit to a nine-month hospitalbased care regimen. To address family concerns, the community constructed a traditional open-air meeting house adjacent to the isolation ward. The Australian Respiratory Council provided funding for a local schoolteacher, and classes were held in the meeting house during the nine months of hospitalization. Donations from the nearby Commonwealth of the Northern Mariana Islands and from Hawaii helped create a positive living environment for the MDR-TB patients and their families. Several authors have documented the importance of a patient-centered approach toward achieving compliance with difficult TB treatment regimens. 5, 6 In Chuuk, these family-centered services contributed greatly toward treatment adherence and were key to the eventual clinical success. 
EVALUATION
In Chuuk, the discovery of MDR-TB overwhelmed the existing capacity of the local public health department and led local officials to declare a state of emergency. The outbreak of MDR-TB was facilitated by the use of self-administered therapy and poor monitoring of adherence, limited isolation procedures and infection control practices in health care settings, limited access to health care services because of transportation challenges and remoteness of populations, lack of active case finding through contact investigations, and limited outreach for patient education.
Nevertheless, the most important factor contributing to the transmission of MDR-TB was delayed access to effective second-line medications, which resulted in prolonged infectious periods. Beginning in December 2007, several efforts to obtain second-line medications were unsuccessful. More than one year passed between the first recognized MDR-TB case and the arrival of second-line medications. Much of the delay was caused by inadequate local finances. The direct medical cost of MDR-TB in the United States can be as much as $137 000 per case, not including associated contact investigation costs. 8 In small countries like Micronesia, where the annual TB control budget is US $170 000, a single MDR-TB case can easily overwhelm local resources. Appropriately, resources and technical assistance from outside agencies facilitated remarkable and sustainable advancements by the local TB control program. Within six months, all patients with active TB disease were treated with DOT, a reconstructed 18-bed isolation ward was created, second-line therapy was procured for all patients with MDR-TB disease or latent MDR-TB infection, and contact investigations were conducted on all newly identified smear-positive patients. Furthermore, an additional public health physician, 5 nurses, and 18 DOT workers were hired, and TB program staff members now regularly engage in educational sessions for the public about TB disease, treatment, and prevention. A particularly noteworthy accomplishment is that in the 12 months following implementation of these programmatic improvements, TB mortality in Chuuk dropped from 11% of all TB cases to less than 1% (US mortality rate is 5%), despite a significant increase in the number and complexity of treated cases. Figures 1 and 2 display the remarkable program improvements demonstrated by the Chuuk TB program.
Many of these program improvements were funded by the US Department of the Interior, through prior unused funds originally granted to Micronesia. However, this outbreak prompted the program to reprioritize local resources for the growing TB problem. To ensure sustainability, many program enhancements have already been absorbed by the local budget, including DOT worker salaries and inpatient care costs for MDR cases. Other improvements, including remodeling costs and the purchase of digital x-ray technology, vehicles, and most of the second-line drug supplies, were onetime expenditures that will improve local capacity for years to come.
CONCLUSIONS
MDR-TB is a growing challenge to all regions of the world. TB control programs that are not achieving basic standards can create MDR-TB cases because of inadequate DOT. These same programs will likely have a difficult time managing the costs of treating MDR-TB cases. Small TB programs may struggle to manage outbreaks in a timely manner. Avoidable delays in Chuuk resulted in the surprisingly rapid expansion of infectious cases and contacts with latent MDR-TB disease, which caused the potential for MDR-TB to be firmly entrenched in the community for many years.
To prevent the unnecessary spread of this costly disease, vulnerable TB programs must undertake programmatic improvements to effectively manage the threat of MDR-TB. Regional partners with experienced consultants should work to ensure adequate local capacity for MDR TB management prior to the arrival of the first case. Rapid access to second-line drugs must be ensured for all programs to prevent the spread of drug-resistant Source. Photo by S. Bamrah.
FIGURE 3-Effective, life-saving second-line drugs were not obtained for more than one year after the first case was identified, resulting in a larger number of secondary cases.
Source. Photo by R. Brostrom.
FIGURE 4-An isolation and treatment facility was constructed to manage the cases. More than half of the MDR-TB outbreak cases were in children.
TB, and directly observed therapy must be utilized for all TB cases to prevent the development of drug resistance. Safe isolation and treatment facilities should be available to TB programs, and access to quality laboratory services for culture and drug-susceptibility testing must be ensured. Additionally, clinical and programmatic training should be available for all TB control programs. To prevent a local public health crisis, smaller programs must achieve these fundamental TB control strategies before the arrival of their first MDR case. j
